Egrifta (Tesamorelin) Self-Injection Technique: What Every Woman Needs to Know

What Tesamorelin Is and Why It Is Prescribed to Women

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates the pulsatile release of endogenous growth hormone (GH). The resulting GH surge drives IGF-1 production in the liver, which then reduces visceral adipose tissue (VAT) accumulation.

The FDA approved tesamorelin in 2010 specifically for HIV-infected adults with lipodystrophy. This syndrome arises from both HIV itself and from older antiretroviral drugs, particularly thymidine analogue NRTIs, which alter fat distribution. Women living with HIV develop lipodystrophy at comparable rates to men, yet the clinical picture can differ: women often carry more subcutaneous fat loss in the face and limbs alongside central VAT gain, which interacts with the hormonal shifts of perimenopause and postmenopause.

How the Mechanism Works in Women Specifically

GH secretion is not sex-neutral. Women in their reproductive years have higher GH pulse amplitude than men, driven by the combination between estradiol and endogenous GHRH. Research published in the Journal of Clinical Endocrinology and Metabolism confirms that endogenous estradiol amplifies GH secretion, meaning a woman's baseline GH axis is already hormonally calibrated.

After menopause, estrogen drops sharply and GH pulse amplitude declines. Women on oral estrogen (not transdermal) have reduced GH bioavailability because oral estrogen increases growth-hormone binding protein and suppresses IGF-1. This is directly relevant to your tesamorelin response: if you are a postmenopausal woman taking oral HRT while using Egrifta, your IGF-1 response may be blunted compared to a woman not on oral estrogen.

PCOS, Insulin Resistance, and Visceral Fat

Women with polycystic ovary syndrome (PCOS) carry a disproportionate visceral fat burden even at lower BMI. Although tesamorelin is not approved for PCOS-related VAT accumulation, understanding how GH affects insulin sensitivity matters. Tesamorelin transiently raises fasting glucose and insulin resistance in some patients. For women with PCOS who also have HIV-associated lipodystrophy, careful glucose monitoring is non-negotiable from the first week of therapy.

How Tesamorelin Works: The Mechanism in Plain Terms

Tesamorelin does not deliver GH directly. It mimics the body's natural signal to the pituitary gland to produce GH in its normal pulsatile pattern. This is a meaningful difference from injecting recombinant GH: the pulsatile pattern preserves the physiological ratio of GH isoforms and reduces the supraphysiologic spikes that drive side effects.

Once GH rises, the liver releases IGF-1. In the key Phase 3 trial by Falutz et al. (NEJM, 2007), 412 HIV-infected patients received 2 mg tesamorelin or placebo daily for 26 weeks. The tesamorelin group reduced VAT by approximately 15% versus an increase in the placebo group, a statistically significant and clinically meaningful difference. Trunk fat measured by DEXA and VAT measured by CT both improved.

IGF-1 levels rose by roughly 114% from baseline in the treatment group. That rise is the biomarker your clinician will monitor to confirm that the drug is working and that you are not over-responding.

Why VAT Matters More Than Subcutaneous Fat

Visceral fat is metabolically active in ways that subcutaneous fat is not. It secretes inflammatory cytokines, drives insulin resistance, and is independently associated with cardiovascular risk. Women with HIV-associated lipodystrophy carry a particularly elevated cardiovascular risk profile, and reducing VAT produces measurable improvements in triglycerides and lipid ratios even within 26 weeks, as the Falutz data showed.

Preparing Your Tesamorelin Injection: Step-by-Step

Every injection of tesamorelin requires reconstitution. The drug ships as a lyophilized (freeze-dried) powder in a single-use vial, accompanied by a separate sterile water (bacteriostatic water) vial. You will mix these before each dose.

Gather everything before you start. Rushing the prep step is where most injection errors happen.

What You Need

• One 2 mg tesamorelin vial (powder)
• One vial of sterile water for injection (provided with the kit)
• Two alcohol swabs
• One 1 mL syringe with a thin needle (23- to 25-gauge, 5/8 inch is standard)
• A clean, flat surface
• A sharps disposal container

Reconstitution Procedure

1. Wash hands with soap and water for at least 20 seconds. Dry completely.
2. Remove both vials from the refrigerator. Let them sit at room temperature for 10 minutes. Cold solution increases injection discomfort and may affect mixing.
3. Wipe both vial tops with separate alcohol swabs. Let them air-dry for 30 seconds each. Do not blow on them.
4. Draw 2.1 mL of sterile water into the syringe.
5. Insert the needle into the tesamorelin powder vial at a slight angle and inject the sterile water slowly down the inner wall of the vial. Do not inject directly onto the powder cake; this can denature the peptide.
6. Gently roll the vial between your palms for 30 seconds. Do not shake it. Shaking creates foam and can degrade the molecule.
7. Inspect the solution. The reconstituted product should be clear and colorless. If it is cloudy, discolored, or contains particles, discard it.
8. Draw the full dose into the syringe. Tap out air bubbles before injecting.

Injection Technique: The Abdomen Is the Only Approved Site

The Egrifta prescribing information specifies subcutaneous injection into the abdomen. Unlike many other injectable medications, tesamorelin is not approved for thigh or upper arm injection.

For women, abdominal anatomy varies considerably across reproductive stages. During the late luteal phase, progesterone causes fluid retention and mild bloating; the tissue may feel different. During pregnancy, tesamorelin is contraindicated entirely (see the pregnancy section below). After menopause, redistribution of subcutaneous abdominal fat creates different tissue depth, but the injection technique remains the same.

Site Selection Within the Abdomen

• Stay at least 2 inches away from your navel (umbilicus). Scar tissue and fibrous bands around the navel reduce drug absorption.
• Avoid any area with a scar, stretch mark, bruise, redness, or visible nodule.
• Rotate your injection site each day. A practical method: divide your abdomen into a clock face and rotate clockwise daily, starting at noon and working around. Returning to the same spot within a week causes lipohypertrophy (lumpy, hardened tissue), which then absorbs the drug erratically.
• Stay at least 2 inches away from any site that is tender or shows a previous injection reaction.

The Injection Itself

1. Sit or recline comfortably. Tension in the abdominal wall makes injection harder.
2. Pinch a fold of skin and subcutaneous tissue between your thumb and index finger. Aim for at least a 1-inch fold if your tissue allows.
3. Insert the needle at a 45-degree angle for thinner abdominal walls, or 90 degrees if you have at least 2 cm of subcutaneous tissue. Most women will start at 45 degrees.
4. Release the skin pinch before injecting the solution.
5. Push the plunger steadily over 5 to 10 seconds. Injecting too fast increases local discomfort.
6. Withdraw the needle at the same angle it entered. Do not rub the site afterward; this accelerates local irritation.
7. Apply gentle pressure with a dry cotton ball for 10 to 15 seconds if there is minor bleeding.
8. Dispose of the needle and syringe immediately in your sharps container. Never recap.

Timing Your Injection

Inject once daily, preferably at the same time each night before bed. Growth hormone is naturally secreted in pulses during slow-wave sleep, and evening dosing aligns the tesamorelin-driven GH pulse with this physiological window. Missing a dose? Take it as soon as you remember the same day. If it is the next morning, skip that dose and resume your normal schedule. Do not double up.

Storage and Handling

Unopened vials must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Do not freeze. Keep vials in the original carton to protect them from light.

Once reconstituted, use the solution immediately. The prescribing label states that reconstituted tesamorelin should not be stored and must be injected right after mixing. Prepare each dose fresh.

If the vial has been out of the refrigerator for more than 3 hours, discard it.

Sex-Specific Side Effects and What to Watch For Across Life Stages

Injection Site Reactions

Local reactions (redness, itching, swelling, bruising) occur in roughly 25% of patients in clinical trials. Women tend to report injection site discomfort more consistently than men in GH-axis drug studies, though dedicated sex-stratified side-effect data for tesamorelin specifically is sparse. This is a real evidence gap: the key Falutz trial enrolled predominantly male subjects, as is common in HIV therapeutic trials.

A practical monitoring framework for women by life stage:

• Reproductive years (cycling women): Track injection site reactions in relation to your cycle. Skin sensitivity often peaks in the late luteal phase (days 21 to 28) due to progesterone-driven mast cell activity. If reactions worsen cyclically, timing your injection earlier in the evening and using a slightly shorter needle may reduce discomfort.
• Perimenopause: Fluctuating estrogen causes variable skin thickness and hydration. Injection sites may bruise more easily during low-estrogen stretches. Document your reaction pattern month to month.
• Postmenopause: Skin atrophy reduces subcutaneous fat depth in some women. Confirm with your clinician whether a 45-degree angle remains appropriate or whether a shorter needle (1/2 inch) is more suitable for your tissue depth.

Glucose and Insulin Effects

Tesamorelin raises IGF-1, and elevated IGF-1 can cause transient insulin resistance. The Falutz et al. 2010 follow-up study in NEJM showed that glucose metabolism changes, while modest, were measurable. Women with PCOS or a personal history of gestational diabetes carry baseline insulin resistance, making glucose monitoring particularly relevant. Check fasting glucose at baseline, 3 months, and 6 months at a minimum.

Edema and Fluid Retention

GH axis activation causes sodium and water retention. Peripheral edema and joint pain (arthralgias) are the most common systemic side effects. Women in the late luteal phase already retain fluid; tesamorelin can amplify this. If you notice significant ankle swelling or joint stiffness that began after starting therapy, contact your prescriber before your next injection.

IGF-1 Monitoring

The Egrifta prescribing information recommends checking IGF-1 levels approximately 6 months after starting therapy. Values consistently above 3.0 SDS (standard deviations above the age- and sex-adjusted mean) signal over-response and warrant dose review. Sex- and age-adjusted IGF-1 reference ranges matter here: a 48-year-old perimenopausal woman has a different normal IGF-1 range than a 35-year-old cycling woman.

Pregnancy, Lactation, and Contraception: What You Must Know

Tesamorelin is contraindicated in pregnancy. If you become pregnant while using Egrifta, stop the injections immediately and contact your prescriber.

Pregnancy Category and Human Data

Tesamorelin carries FDA Pregnancy Category X. Animal reproductive studies showed fetal harm at doses that produced systemic exposure below the human therapeutic dose. No adequate human pregnancy data exist. Because GH axis dysregulation during fetal development carries theoretical risks for fetal growth and pancreatic beta-cell programming, the risk-benefit calculation is definitively against use.

Women of reproductive age using tesamorelin must use reliable contraception throughout the course of therapy. If you are also on antiretroviral therapy, be aware that some ARVs (particularly rifamycin-based regimens used for TB coinfection) reduce hormonal contraceptive efficacy. Discuss your full medication list with your clinician to confirm contraceptive adequacy.

Lactation

Whether tesamorelin passes into human breast milk is unknown. The Egrifta label advises against use in breastfeeding women because GH-axis peptides may transfer and the potential effect on a nursing infant's growth axis has not been studied. Women with HIV are generally advised not to breastfeed in resource-adequate settings due to transmission risk, which independently removes the lactation dilemma for most HIV-positive women in the US.

Postpartum Considerations

For women who have recently delivered and are not breastfeeding, restart of tesamorelin should be discussed with your care team once your postpartum hormonal milieu has stabilized. Postpartum physiology includes transient hypoprolactinemia and rapidly shifting estrogen levels that affect the GH axis independently of tesamorelin.

Hormone Therapy Interactions: Oral Versus Transdermal Estrogen

This is a clinically significant interaction that is poorly communicated to women patients.

Oral estrogen (taken by mouth) undergoes first-pass liver metabolism, which upregulates growth-hormone binding protein (GHBP) and suppresses hepatic IGF-1 production. The net effect is that oral estrogen blunts the IGF-1 rise you would otherwise get from tesamorelin. Studies in GH-deficient adults demonstrate that oral, but not transdermal, estrogen reduces GH sensitivity, with IGF-1 suppression of up to 30 to 40%.

If you are a perimenopausal or postmenopausal woman taking oral estradiol or conjugated equine estrogens (Premarin) and you start tesamorelin, your IGF-1 may not rise as expected. Your clinician should know your HRT route before interpreting your 6-month IGF-1 result.

Transdermal estradiol (patch, gel, spray) bypasses liver first-pass metabolism and does not suppress IGF-1 to the same degree. If you have a compelling reason to use HRT alongside tesamorelin, transdermal estrogen is the pharmacologically preferable route.

Who This Treatment Is Right For and Who Should Not Use It

Women Most Likely to Benefit

• Women living with HIV who have measurable VAT accumulation on imaging (CT or DEXA)
• Those whose lipodystrophy is causing metabolic consequences: hypertriglyceridemia, early insulin resistance, or cardiovascular risk elevation
• Women who have stabilized their antiretroviral regimen and whose HIV viral load is undetectable
• Postmenopausal women with HIV-associated VAT gain who are not on oral estrogen (or who can switch to transdermal)

Women Who Should Not Use Tesamorelin

• Any woman who is pregnant or planning pregnancy in the near future
• Women with active malignancy or a history of malignancy (GH axis stimulation and IGF-1 elevation are contraindicated in oncology contexts)
• Women with active hypopituitarism or hypothalamic disruption from causes other than HIV
• Women with pituitary tumors or prior pituitary radiation that may cause unpredictable GH responses
• Women with diabetes mellitus that is poorly controlled at baseline (glucose worsening risk)

Perimenopausal and Postmenopausal Women: A Specific Note

The decline in endogenous GHRH and GH secretion that accompanies menopause means the pituitary is more dependent on exogenous GHRH stimulation in older women. Tesamorelin may produce a more pronounced IGF-1 rise in postmenopausal women not on oral estrogen. Your IGF-1 should be checked at 3 months in addition to the standard 6-month check if you are postmenopausal and not on estrogen therapy.

Troubleshooting Common Injection Problems

Air Bubbles in the Syringe

Draw slightly more sterile water than needed (2.1 mL instead of 2 mL exactly), pull the syringe plunger back slightly after filling, then tap the barrel and slowly depress to the correct volume. Small air bubbles in a subcutaneous injection are not dangerous, but eliminating them ensures accurate dosing.

Painful Injections

Letting the vial reach room temperature before reconstitution is the single biggest factor in reducing injection pain. Cold solution stings significantly more. Injecting too quickly also increases discomfort: a 5- to 10-second injection over 0.5 mL is slower than it sounds. Practicing the steady plunger speed with a water-filled syringe before your first real dose is a legitimate preparation technique.

Bruising at the Site

Bruising usually means the needle nicked a small superficial vessel. Rotating sites rigorously reduces this. Avoid sites near the lower costal margins where small vessels are less mobile. If you take low-dose aspirin or an anticoagulant for cardiovascular management, expect more bruising and apply firm pressure for a full 30 seconds post-injection.

Foam or Cloudiness After Mixing

If you shake the vial instead of rolling it, the solution foams. Foam contains denatured peptide and should be discarded. Let a foamy vial sit undisturbed for 2 minutes; if the foam resolves and the solution clears, it may still be usable. Persistent cloudiness after 3 minutes means the product is degraded. Discard and prepare a fresh vial.

Monitoring Plan: A Practical Timeline for Women

| Timepoint | Test | Why It Matters for Women | |---|---|---| | Baseline | Fasting glucose, HbA1c, IGF-1, fasting lipids, CT or DEXA for VAT | Establishes whether VAT reduction is measurable; sets glucose and IGF-1 benchmarks | | 3 months | IGF-1, fasting glucose | Postmenopausal women and those not on estrogen may hit peak IGF-1 earlier | | 6 months | IGF-1, fasting lipids, glucose, VAT imaging | Primary efficacy endpoint mirroring Falutz trial design | | 12 months | Full metabolic panel, bone density if other risk factors present | Long-term GH axis stimulation may affect bone turnover markers |

The Falutz 2010 extension study followed patients for 52 weeks and found that VAT reduction was maintained, though partially reversed after drug discontinuation within 6 months of stopping. This matters for women approaching menopause: if natural hormonal changes accelerate VAT gain, stopping tesamorelin may result in faster VAT rebound than in younger women.